Wordt geladen...
Sitravatinib potentiates immune checkpoint blockade in refractory cancer models
Immune checkpoint blockade has achieved significant therapeutic success for a subset of cancer patients; however, a large portion of cancer patients do not respond. Unresponsive tumors are characterized as being immunologically “cold,” indicating that these tumors lack tumor antigen-specific primed...
Bewaard in:
| Gepubliceerd in: | JCI Insight |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society for Clinical Investigation
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6238734/ https://ncbi.nlm.nih.gov/pubmed/30385724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.124184 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|